+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07474324

Phase II Trial Comparing Disitamab Vedotin Plus SOX Chemotherapy Versus SOX Alone as Adjuvant Treatment for HER2-ModerateHigh Expressing Stage III Gastric and Gastroesophageal Junction Cancer

Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2026-03-16

124

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the preliminary effectiveness and safety of combining disitamab vedotin with the SOX chemotherapy regimen compared to SOX alone. This phase II, prospective, multicenter, randomized clinical trial focuses on patients with HER2-moderate to high-expressing stage III gastric or gastroesophageal junction adenocarcinoma who have undergone D2 or more extensive surgery with no prior systemic anti-tumor treatment before surgery. Participants will receive adjuvant therapy starting about four weeks after surgery, with one group treated with disitamab vedotin plus SOX and the other with SOX alone. Treatment consists of 6 to 8 cycles. Post-operative imaging assessments occur every three months to monitor for disease recurrence. Following any recurrence, survival follow-up visits are conducted every three months. Safety visits continue from the first dose until 60 days after the last dose or until a new anti-tumor treatment begins. During the study, participants will undergo regular imaging to assess disease status, and researchers will monitor safety and survival outcomes. The primary outcome is the 3-year disease-free survival rate, with secondary measures including overall survival rates and adverse event incidence over several years. Participants can expect ongoing follow-up for up to five years after treatment to evaluate long-term outcomes.

CONDITIONS

Brief Title

Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here